Adenosine Receptor A3 (ADORA3) - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 60 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Adenosine Receptor A3 (ADORA3) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Adenosine Receptor A3 (ADORA3) - Pipeline Review, H2 2016', provides in depth analysis on Adenosine Receptor A3 (ADORA3) targeted pipeline therapeutics. 

The report provides comprehensive information on the Adenosine Receptor A3 (ADORA3), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Adenosine Receptor A3 (ADORA3)
- The report reviews Adenosine Receptor A3 (ADORA3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Adenosine Receptor A3 (ADORA3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Adenosine Receptor A3 (ADORA3) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Adenosine Receptor A3 (ADORA3)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Adenosine Receptor A3 (ADORA3) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Adenosine Receptor A3 (ADORA3) Overview 6
Therapeutics Development 7
Adenosine Receptor A3 (ADORA3) - Products under Development by Stage of Development 7
Adenosine Receptor A3 (ADORA3) - Products under Development by Therapy Area 8
Adenosine Receptor A3 (ADORA3) - Products under Development by Indication 9
Adenosine Receptor A3 (ADORA3) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Adenosine Receptor A3 (ADORA3) - Products under Development by Companies 14
Adenosine Receptor A3 (ADORA3) - Products under Development by Universities/Institutes 16
Adenosine Receptor A3 (ADORA3) - Therapeutics Assessment 18
Assessment by Monotherapy/Combination Products 18
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Adenosine Receptor A3 (ADORA3) - Companies Involved in Therapeutics Development 24
Can-Fite BioPharma Ltd. 24
Huons Co., Ltd. 25
Adenosine Receptor A3 (ADORA3) - Drug Profiles 26
ACN-1052 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
CF-102 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
CF-602 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
HU-010 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
LJ-1888 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
PBF-1650 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
PBF-677 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
piclidenoson - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Small Molecules to Agonize Adenosine A3 Receptor for Chemotherapy Induced Peripheral Neuropathy - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Adenosine Receptor A3 (ADORA3) - Dormant Projects 46
Adenosine Receptor A3 (ADORA3) - Discontinued Products 48
Adenosine Receptor A3 (ADORA3) - Featured News & Press Releases 49
Aug 08, 2016: Can-Fites Phase II/III Psoriasis Study Results Published in Journal of Drugs in Dermatology 49
Jul 25, 2016: Can-Fite Completes Phase II Study Design for CF102 in the Treatment of NASH/NAFLD 49
Jul 05, 2016: OphthaliX Announces Phase II Glaucoma Data 50
Jun 15, 2016: Can-Fite Reports New Data Showing its Psoriasis Drug May Offer Efficacy Similar to Industry Leading Biologics Without Harmful Side Effects 50
Jun 07, 2016: Can-Fite Submits Psoriasis Phase III Protocol and Registration Plan to EMA for Piclidenoson (CF101) 51
Jun 01, 2016: Can-Fite Reaches Agreement with EMA on Pivotal Phase III Clinical Trial with Piclidenoson (CF101) in Rheumatoid Arthritis 52
May 02, 2016: Can-Fite to Present Data on CF602 in the Treatment of Erectile Dysfunction at American Urology Association Annual Meeting 52
Apr 11, 2016: Can-Fite Announces New Pre-Clinical Data for CF602 Demonstrating Statistically Significant Full Recovery from Erectile Dysfunction After a Single Dose 53
Mar 17, 2016: Can-Fite Submits Phase III Protocol Design and Registration Plan to European Medicines Agency (EMA) for CF101 in the Treatment of Rheumatoid Arthritis 53
Jan 19, 2016: U.S. Patent & Trademark Office Issues Notice of Allowance for Can-Fite's Sexual Dysfunction Drug CF602 54
Jan 11, 2016: Can-Fite Announces Update on CF101 55
Jan 11, 2016: Can-Fite Announces Update on CF102 55
Jan 11, 2016: Can-Fite Announces Update on CF602 56
Jan 05, 2016: Can-Fite Submits Phase III Protocol to IRB for CF101 in the Treatment of Rheumatoid Arthritis 56
Dec 17, 2015: Can-Fite's CF101 Granted Patent in Japan for Intraocular Pressure a Key Cause of Glaucoma 57
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 58
Disclaimer 59

List of Tables

Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Comparative Analysis by Unknown Stage Development, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Products under Development by Companies, H2 2016 15
Number of Products under Investigation by Universities/Institutes, H2 2016 16
Products under Investigation by Universities/Institutes, H2 2016 17
Assessment by Monotherapy/Combination Products, H2 2016 18
Number of Products by Stage and Mechanism of Action, H2 2016 20
Number of Products by Stage and Route of Administration, H2 2016 22
Number of Products by Stage and Molecule Type, H2 2016 23
Pipeline by Can-Fite BioPharma Ltd., H2 2016 24
Pipeline by Huons Co., Ltd., H2 2016 25
Dormant Projects, H2 2016 46
Dormant Projects (Contd..1), H2 2016 47
Discontinued Products, H2 2016 48